Grand Pharmaceutical Group Ltd

Grand Pharmaceutical Group Ltd maintains a relatively strong liquidity position, with a current ratio of 1.14, indicating that its current assets slightly exceed its current liabilities. However, the company's free cash flow is negative at -606.38 million HKD, and capital expenditures are significant at -1.52 billion HKD, suggesting ongoing investment in operations. The company's debt-to-equity ratio is 0.28, which is relatively low, indicating a conservative capital structure.

In terms of profitability, the company's return on equity (ROE) is 7.29%, and its return on assets (ROA) is 4.57%, both of which are positive but should be compared to industry medians to assess relative performance. The company's net income of 1.24 billion HKD and operating income of 1.58 billion HKD reflect a healthy level of profitability. Gross profit of 6.78 billion HKD suggests strong cost control in production.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of geographic segmentation may indicate a high concentration of revenue in a specific region, which could pose a concentration risk if not disclosed in the input data.

Looking ahead, the company's revenue is expected to grow, though the exact growth rate is not provided in the input data. Analysts have provided a mean price target of 11.85 HKD, with a median of 11.85 HKD, and a high of 12.00 HKD, indicating a generally positive outlook. The mean recommendation is 1.50, which is a strong buy signal, with two strong-buy and two buy ratings.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully to avoid liquidity constraints. The dilution risk is low, and there is no indication of near-term dilution pressure in the input data.

Recent events, including analyst estimates and price targets, suggest a positive sentiment among investors. The company has not disclosed any recent filings or transcripts that would indicate significant changes in its business operations or strategic direction.